A Case Report: 19-Year-Old Hispanic Young Woman with Early-Stage Breast Cancer and a Germline Pathogenic Variant
Main Article Content
Abstract
Background: Breast cancer (BC) is the most common cancer diagnosed in women globally and the leading cause of cancer-related deaths among younger women diagnosed between the ages of 20-49 years in the United States (US). Although the median age of BC diagnosis is 62 years overall, recent data show that early-onset BC is on the rise in young people. Black and Hispanic women are disproportionately affected by BC, often diagnosed at a younger age, and BC is the leading cause of cancer-related deaths for both groups of women. The aim of this report is to present the unique case of a young adult Hispanic woman diagnosed with early-stage BC. Younger women with BC face unique biological and psychosocial challenges compared to older post-menopausal women. Additionally, young breast cancer survivors (YBCS) are at an increased risk of BC recurrence. Therefore, there is a critical need to develop interventions that are tailored to the cultural and age-specific needs of racial and ethnic minority women to promote cancer risk-reduction and to improve health outcomes.
Method: Case Report: We present the case of a 19-year-old Hispanic female with no family history of breast cancer (BC), who was diagnosed with ductal carcinoma in situ (DCIS). Initially diagnosed in 2018, she received treatment at a comprehensive cancer center. At the time of diagnosis, she completed multigene panel testing to identify hereditary cancer risk. The testing revealed a pathogenic variant in the PTEN gene. The patient underwent a bilateral mastectomy as part of her treatment plan due to her high-risk status. Five years post-diagnosis, in 2023 she joined our NIH-funded research study focused on investigating the experiences and needs of young breast cancer survivors (YBCS) from diverse racial and ethnic backgrounds.
Conclusion:Women are being diagnosed with BC at increasingly younger ages. This case underscores the need to increase awareness about risk factors among diverse younger women and highlights the critical role of genetic testing in identifying hereditary breast and ovarian cancer (HBOC) syndrome and using that knowledge for informed decision-making. This is especially important for racial and ethnic minority women who suffer disproportionately from BC outcomes. Furthermore, it emphasizes the importance of a holistic approach to care, grounded in caring science, which prioritizes the well-being of the whole person. Nurses, in collaboration with other healthcare providers, are in a unique position to positively impact the lives of young breast cancer patients, survivors, and those at high-risk for developing the disease. By advocating for early detection, tailored age-appropriate interventions, and comprehensive support, nurses can significantly improve health outcomes and empower young women to live longer, healthier lives. Future research should investigate the complex interaction between biological, psychological, social, and environmental factors in order to reduce cancer health disparities and improve health for all.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Xu S, Murtagh S, Han Y, Wan F, Toriola AT. Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status. JAMA Network Open. 2024;7(1):e2353331.
3. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208(3):341-347.
4. Jones T, Lockhart JS, Mendelsohn-Victor KE, et al. Use of Cancer Genetics Services in African-American Young Breast Cancer Survivors. American Journal of Preventive Medicine. 2016;51(4):427-436.
5. Jones T, Katapodi MC, Lockhart JS. Factors influencing breast cancer screening and risk assessment among young African American women: An integrative review of the literature. Journal of the American Association of Nurse Practitioners. 2015;27(9):521-529.
6. American Cancer Society (ACS). Breast Cancer Facts & Figures 2024-2025. Atlanta 2024.Retrived from https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf
7. Koh B, Tan DJH, Ng CH, et al. Patterns in Cancer Incidence Among People Younger Than 50 Years in the US, 2010 to 2019. JAMA Network Open. 2023;6(8):e2328171.
8. Cathcart-Rake EJ, Ruddy KJ, Bleyer A, Johnson RH. Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years. JCO Oncology Practice. 2021;17(6):305-313.
9. Chen D, Zhang C, Yuan M, Zhang Y, Liu Q, Wan D. Adolescent triple-negative breast cancer with germline pathogenic variants in both BRCA1 and TP53 genes: A case report. Frontiers in oncology. 2022;12:970641.
10. Chen JC, Stover DG, Ballinger TJ, et al. Racial Disparities in Breast Cancer: from Detection to Treatment. Current Oncology Reports. 2024;26(1):10-20.
11. Costa L, Kumar R, Villarreal-Garza C, et al. Diagnostic delays in breast cancer among young women: An emphasis on healthcare providers. Breast (Edinburgh, Scotland). 2024;73:103623.
12. National Cancer Institute (NCI). BRCA Gene Changes: Cancer Risk and Genetic Testing. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#:~:text=People%20who%20inherit%20a%20harmful,not%20have%20such%20a%20variant. Published 2024. Updated July 19, 2024.
13. Fernández Madrigal L, Rodríguez Garcés MY, Jiménez Ruiz FJ. Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC). Current Problems in Cancer. 2023;47(6):101008.
14. Su Y, Yao Q, Xu Y, et al. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions. Frontiers in genetics. 2021;12:674094.
15. Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Annals of oncology: Official Journal of the European Society for Medical Oncology. 2015;26(7):1291-1299.
16. Jones T, McCarthy AM, Kim Y, Armstrong K. Predictors of BRCA1/2 genetic testing among Black women with breast cancer: a population-based study. Cancer medicine. 2017;6(7):1787-1798.
17. Jones T, Trivedi MS, Jiang X, et al. Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients. Journal of Cancer Education: The official Journal of the American Association for Cancer Education. 2021;36(3):463-469.
18. Bergerot CD, Philip EJ, Bergerot PG, Siddiq N, Tinianov S, Lustberg M. Fear of Cancer Recurrence or Progression: What Is It and What Can We Do About It? American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting. 2022;42:1-10.
19. Gudenkauf LM, Ehlers SL. Psychosocial interventions in breast cancer survivorship care. Breast (Edinburgh, Scotland). 2018;38:1-6.
20. Williams AD, LaRoy J, Le T, et al. Clinical Challenges in Breast Care for Patients with PTEN Pathogenic Variants: A Case Series and Literature Review. Surgical Oncology Insight. 2024:100016.
21. Mima K, Hamada T, Inamura K, Baba H, Ugai T, Ogino S. The microbiome and rise of early-onset cancers: knowledge gaps and research opportunities. Gut microbes. 2023;15(2):2269623.
22. Ellington TD, Miller JW, Henley SJ, Wilson RJ, Wu M, Richardson LC. Trends in Breast Cancer Incidence, by Race, Ethnicity, and Age Among Women Aged ≥20 Years - United States, 1999-2018. MMWR Morbidity and mortality weekly report. 2022;71(2):43-47.
23. Ugai T, Sasamoto N, Lee HY, et al. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nature reviews Clinical oncology. 2022;19(10):656-673.
24. Mima K, Kosumi K, Baba Y, Hamada T, Baba H, Ogino S. The microbiome, genetics, and gastrointestinal neoplasms: the evolving field of molecular pathological epidemiology to analyze the tumor-immune-microbiome interaction. Human genetics. 2021;140(5):725-746.
25. Hamada T, Nowak JA, Milner DA, Jr., Song M, Ogino S. Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. The Journal of pathology. 2019;247(5):615-628.
26. Michel A, Dorval M, Chiquette J, Savard J. Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study. Hereditary cancer in clinical practice. 2024;22(1):16.
27. Wang YZ, Li L, Pang ZL. Role of peer support on fear of cancer recurrence in patients with breast cancer. Journal of Advanced Nursing. 2024.
28. Katapodi M, Ngeow J, Yie Y, Frey M. Editorial for familial cancer: cascade genetic testing. Familial Cancer. 2024;23(2):109-110.
29. Cowling WR, 3rd, Smith MC, Watson J. The power of wholeness, consciousness, and caring a dialogue on nursing science, art, and healing. ANS Advances in Nursing Science. 2008;31(1):E41-51.
30. Watson J. Revisiting 'Discipline' in Relation to Caring Science as Sacred Science: Revisiting Discipline of Nursing. Journal of Holistic Nursing: Official Journal of the American Holistic Nurses' Association. 2022;40(1):58-63.
31. Turkel MC, Watson J, Giovannoni J. Caring Science or Science of Caring. Nursing science quarterly. 2018;31(1):66-71.
32. Boykin A. Nursing as Caring: A Model for Transforming Practice. Jones & Bartlett Learning; 2001.
33. Wei H, Hardin SR, Watson J. A unitary caring science resilience-building model: Unifying the human caring theory and research-informed psychology and neuroscience evidence. International Journal of Nursing Sciences. 2021;8(1):130-135.
34. Nicholson WK, Silverstein M, Wong JB, et al. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;331(22):1918-1930.
35. Giannakeas V, Lim DW, Narod SA. Bilateral Mastectomy and Breast Cancer Mortality. JAMA Oncology. 2024;10(9):1228-1236.
36. Giannakeas V, Narod SA. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer. 2019;125(12):2130.
37. Rathmell WK. Using the National Cancer Plan to Drive Innovation in Cancer Research. Cancer Discovery. 2024;14(4):555-558.
38. Collins IM, Bickerstaffe A, Ranaweera T, et al. iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management. Breast Cancer Research and Treatment. 2016;156(1):171-182.